Published • loading... • Updated
Aldevron, Minaris Expand Cell Therapy Supply Pact
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Aldevron, Minaris Expand Cell Therapy Supply Pact
PHILADELPHIA, PA — Aldevron, a unit of Danaher Corporation (NYSE: DHR), and Minaris expanded a licensing agreement tied to lentiviral plasmid manufacturing, deepening a partnership aimed at accelerating development timelines for gene-modified cell therapies including CAR-T treatments. The renewed agreement gives biotechnology developers broader access to an off-the-shelf lentiviral plasmid system used in cell and gene therapy manufacturing, an a…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
